Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis

Vidmantas Petraitis; Ruta Petraitiene; Pengxin Lin; Karim Calis; Amy M. Kelaher; Heidi A. Muray; Christine Mya-San; Diana Mickiene; John Bacher; Thomas J. Walsh

doi:10.1128/AAC.49.4.1642-1645.2005

Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis

Vidmantas Petraitis
, Ruta Petraitiene
, Pengxin Lin
, Karim Calis
, Amy M. Kelaher
, Heidi A. Muray
, Christine Mya-San
, Diana Mickiene
, John Bacher
, Thomas J. Walsh

Center for Discovery and Innovation

National Institutes of Health
SAIC
Office of Research Services

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.

Original language	English
Pages (from-to)	1642-1645
Number of pages	4
Journal	Antimicrobial Agents and Chemotherapy
Volume	49
Issue number	4
DOIs	https://doi.org/10.1128/AAC.49.4.1642-1645.2005
State	Published - Apr 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.49.4.1642-1645.2005

Cite this

@article{380511b3643b464b9c560a9509667467,

title = "Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis",

abstract = "The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.",

author = "Vidmantas Petraitis and Ruta Petraitiene and Pengxin Lin and Karim Calis and Kelaher, \{Amy M.\} and Muray, \{Heidi A.\} and Christine Mya-San and Diana Mickiene and John Bacher and Walsh, \{Thomas J.\}",

year = "2005",

month = apr,

doi = "10.1128/AAC.49.4.1642-1645.2005",

language = "English",

volume = "49",

pages = "1642--1645",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "4",

}

TY - JOUR

T1 - Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis

AU - Petraitis, Vidmantas

AU - Petraitiene, Ruta

AU - Lin, Pengxin

AU - Calis, Karim

AU - Kelaher, Amy M.

AU - Muray, Heidi A.

AU - Mya-San, Christine

AU - Mickiene, Diana

AU - Bacher, John

AU - Walsh, Thomas J.

PY - 2005/4

Y1 - 2005/4

N2 - The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.

AB - The recent shortage of the brand name drug Fungizone has necessitated a change to generic formulations of amphotericin B deoxycholate. Clinical trials cannot be conducted in a timely manner to provide data on the safety and efficacy of these formulations. We therefore compared generic amphotericin B and Fungizone for activity and safety in the treatment of experimental invasive pulmonary aspergillosis (IPA) in persistently neutropenic rabbits. Fungizone and generic amphotericin B are similar in efficacy, pharmacokinetics, and safety in the treatment of experimental IPA.

UR - https://www.scopus.com/pages/publications/20144389443

U2 - 10.1128/AAC.49.4.1642-1645.2005

DO - 10.1128/AAC.49.4.1642-1645.2005

M3 - Article

C2 - 15793161

AN - SCOPUS:20144389443

SN - 0066-4804

VL - 49

SP - 1642

EP - 1645

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 4

ER -

Efficacy and safety of generic amphotericin B in experimental pulmonary aspergillosis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this